Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study

Open access
van Rijsingen, Ingrid A.W., van der Zwaag, Paul A., Groeneweg, Judith A., Nannenberg, Eline A., Jongbloed, Jan D.H., Zwinderman, Aeilko H., Pinto, Yigal M., dit Deprez, Ronald H. Lekanne, Post, Jan G., Tan, Hanno L., de Boer, Rudolf A., Hauer, Richard N.W., Christiaans, Imke, van den Berg, Maarten P., van Tintelen, J. Peter, Wilde, Arthur A.M. · 2014 · Circulation: Cardiovascular Genetics

Abstract

Background—: The pathogenic phospholamban R14del mutation causes dilated and arrhythmogenic right ventricular cardiomyopathies and is associated with an increased risk of malignant ventricular arrhythmias and end-stage heart failure. We performed a multicentre study to evaluate mortality, cardiac disease outcome, and risk factors for malignant ventricular arrhythmias in a cohort of phospholamban R14del mutation carriers. Methods and Results—: Using the family tree mortality ratio method in a cohort of 403 phospholamban R14del mutation carriers, we found a standardized mortality ratio of 1.7 (95% confidence interval, 1.4–2.0) with significant excess mortality starting from the age of 25 years. Cardiological data were available for 295 carriers. In a median follow-up period of 42 months, 55 (19%) individuals had a first episode of malignant ventricular arrhythmias and 33 (11%) had an end-stage heart failure event. The youngest age at which a malignant ventricular arrhythmia occurred was 20 years, whereas for an end-stage heart failure event this was 31 years. Independent risk factors for malignant ventricular arrhythmias were left ventricular ejection fraction <45% and sustained or nonsustained ventricular tachycardia with hazard ratios of 4.0 (95% confidence interval, 1.9–8.1) and 2.6 (95% confidence interval, 1.5–4.5), respectively. Conclusions—: Phospholamban R14del mutation carriers are at high risk for malignant ventricular arrhythmias and end-stage heart failure, with left ventricular ejection fraction <45% and sustained or nonsustained ventricular tachycardia as independent risk factors. High mortality and a poor prognosis are present from late adolescence. Genetic and cardiac screening is, therefore, advised from adolescence onwards.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circgenetics.113.000374

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 190

Metadata

Authors
van Rijsingen, I. A. W., van der Zwaag, P. A., Groeneweg, J. A., Nannenberg, E. A., Jongbloed, J. D. H., Zwinderman, A. H., Pinto, Y. M., dit Deprez, R. H. L., Post, J. G., Tan, H. L., de Boer, R. A., Hauer, R. N. W., Christiaans, I., van den Berg, M. P., van Tintelen, J. P., & Wilde, A. A. M.
Venue
Circulation: Cardiovascular Genetics
Published
2014-08
Volume
7
Issue
4
Pages
455-465
ISSN
  • 1942-325X (ISSN-L)
  • 1942-3268
OpenAlex
W2170124209
Cited by
190
References
5
FWCI
7.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study. https://app.cochat.ai/papers/10.1161/circgenetics.113.000374
The paper
van Rijsingen, I. A. W., van der Zwaag, P. A., Groeneweg, J. A., Nannenberg, E. A., Jongbloed, J. D. H., Zwinderman, A. H., Pinto, Y. M., dit Deprez, R. H. L., Post, J. G., Tan, H. L., de Boer, R. A., Hauer, R. N. W., Christiaans, I., van den Berg, M. P., van Tintelen, J. P., & Wilde, A. A. M. (2014). Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study. Circulation: Cardiovascular Genetics. https://doi.org/10.1161/circgenetics.113.000374

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.